Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Tenax Therapeutics Q3 2026 Results: Net Loss of $16.7M, Loss Widens

Tenax Therapeutics reported a net loss of $50.2 million for the nine months ended September 30, 2026, driven by increased research and development costs for its cardiopulmonary therapies. Despite the loss, the company strengthened its liquidity position to $113.7 million in cash and cash equivalents, primarily through $52.1 million in proceeds from the exercise of warrants and options. Management believes current funds are sufficient to support operations for at least the next 12 months.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-16.7-15.8
EPS (diluted, $ a share)$-0.31$-0.40

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TENX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Tenax Therapeutics, Inc.: key numbers

Share price
$1.48Close, Nov 16
Market cap
$67.4M
Shares outstanding
45.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Tenax Therapeutics, Inc.

All →
4:50 PM ET Form 4
Insider Buying

Tenax Therapeutics Insider ADAR1 Capital Management LLC Buys $1.46M of Stock

ADAR1 Capital Management LLC bought 922,849 shares of Tenax Therapeutics, Inc. at $1.51 to $1.66 a share (average $1.59) in 3 transactions, worth $1.46M in total between Oct 19, 2026 and Oct 21, 2026. Shares held after the trade: 7,447,000 (+4.7%).

Value
$1.46M
Shares
922,849
Average price
$1.59
Holding change
+4.7%
Trade date
Oct 19, 2026 to Oct 21, 2026
4:16 PM ET 8-K
Investor Presentation

Tenax Therapeutics Investor Presentation

Tenax Therapeutics filed an updated investor presentation detailing strategic changes to its Phase 3 LEVEL-2 clinical trial for TNX-103 in PH-HFpEF. The company is pausing enrollment to amend protocol criteria based on findings from its completed LEVEL trial and has requested a Type C meeting with the FDA to discuss the development path.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.